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ABSTRACT 
Background  and  Objectives:  300  Pseudomonas  aeruginosa  strains  were  isolated  from  hospitalized  patients  in 
Iran. Using international antigenic typing system (IATS) antibodies, all strains were classified into 16 serotypes while 
serotype 14 was not identified among the 17 known serotypes. To evaluate the rate of cross-reactivity between O- antigenic 
determinants, monospecific polyclonal antibodies were made against whole-killed-cells and live cells of each serotype.
Material and Methods: Each antiserum was challenged against homologous and heterologous antigens using slide 
agglutination test. The degree of agglutination reaction is shown by –ve, 1+ve, 2+ve, 3+ve and 4+ve for 0, 25%, 50%, 
75% and 100% agglutination respectively. Then, the results were tabulated for further study. 
Results: The rate of cross-reactivity between O-antigenic determinants demonstrated that strains 10.55 and 15.14 had the 
highest agglutination reaction with serum of all the homologous and heterologous serotypes.
Conclusion: Evaluation of the results obtained from the present study can be applied in production of reliable vaccines and 
antisera as therapeutic agents or as diagnostic kits. 
Keywords: Pseudomonas aeruginosa, agglutination test, cross-reactivity, antigenic schema.
INTRODUCTION
Pseudomonas  aeruginosa  is  one  of  the  most 
common  opportunistic  pathogen  of  nosocomial 
infections (1- 9). Being amphibiotic in nature (parasite 
& saprophyte), P. aeruginosa causes a high epidemic 
spread in wound and burn infections and in patients 
with immune deficiency syndrome, neoplasia, cystic 
fibrosis,  ones  who  have  undergone  surgery,  organ 
transplantation or have received artificial organs (2, 
3, 5, 6, 9, 10).
Based  on  the  antigenic  specification  of  the 
oligosaccharide side chain of LPS (O-Antigen), many 
serological classification systems for P. aeruginosa 
were proposed (11- 14), but the most reliable typing 
system was the one suggested by the International 
Committee  of  Microbiology  (ICM)  in  1970  which 
adapted  17  heat  stable  O-antigenic  typing  system 
abbreviated by arabic numbers 1 through 17 (1, 7).
In the present study, we have performed the slide 
agglutination test according to the panel of the ICM 
typing system, using 300 pathogenic P. aeruginosa 
isolates  collected  from  different  hospitals  in  Iran 
to suggest a new model of antigenic schema for P. 
aeruginosa serotyping so that, to control or prevent 
the infection.
MATERIALS  AND METHODS
Bacterial  strains.  Applying  biochemical  tests 
and  using  standard  somatic  typing  antisera  from 
Difco (Franklin Lakes, NJ USA) & Denka Seiken 
(Tokyo, Japan) Companies, all 300 clinical isolates 
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Antiserum
                     
      Antigen 
4+ 2+ __ __ __ __ __ __ 2+ __ 2+ 2+ __ __ __ __ __ __ 2+ 2+ 4+ 1:101       
__ __ 4+ __ 4+ __ __ __ 1+ __ __ 2+ __ __ 1+ __ 4+  __ 1+ 4+ __ 2:160       
__ 1+ __ __ __ __ __ __ 3+ __ __ 4+  __ __ __ 4+ __ __ 4+  __ __ 3:172       
__ __ __ __ __ __ __ __ __ 4+ 4+ __ 4+ 1+ 3+ __ __ 4+ __ __ __ 4:89         
__ +3 __ __ __ 3+ 3+ __ 3+ __ __ __ __ __ __ 1+ 4+  1+ __ 3+ 1+ 5:60         
__ __ 4+ __ 4+  __ __ __ __ __ __ __ __ __ __ 4+ 4+ __ __ 4+ __ 5:111       
__ 4+ __ __ __ __ __ __ __ 4+  4+  __ 4+ 4+  4+ __ __ __ __ __ __ 6:95         
__ 4+ __ __ __ __ __ __ __ +4 4+ __ 4+  4+  4+  __ __ 4+ __ __ __ 6:109       
__ 4+ __ __ __ __ __ __ __ 4+ 4+ __ 4+ 4+  3+ __ __ 3+ __ __ __ 7:107       
__ __ __ __ __ __ __ __ __ __ __ 4+ __ __ 2+ __ __ __ 4+ __ __ 7:197       
__ 4+ __ __ __ __ __ __ __ 4+ 4+  __ 4+ 4+ 4+  __ __ 4+ __ __ 1+ 8:98             
_ 2+ __ __ __ __ __ __ 1+ 4+ 1+ __ __ 1+ __ 3+ 1+ __ 3+ __ 3+ 9:105       
4+ 4+ __ 2+ __ __ __ __ 4+  4+  1+ 4+ 4+  4+  __ 4+ 4+  4+ 4+ 4+ 4+  10:55 
__ __ __ __ __ __ __ 4+ 4+ __ __ __ __ __ __ __ __ __ __ __ __ 11:106     
__ __ 1+ __ __ 4+  4+  __ __ __ __ __ __ __ __ __ __ __ __ __ __ 12:80       
__ __ 1+ 2+ __ 4+ 4+ __ __ 2+ 1+ __ __ __ __ __ __ __ __ __ __ 12:159     
__ __ 4+ __ 4+ __ __ __ __ __ __ __ __ __ __ 4+  4+  __ __ __ __ 13:108        
3+ 4+ 4+  4+ 4+ 4+ 4+ 4+ 4+ __ __ 1+ 4+ 4+ 4+ 4+ 4+ 4+ 2+ 4+ 3+ 15:14       
3+ __ 4+ 4+ 4+  __ __ 4+  __ 1+ __ 1+ 3+ 4+  4+  1+ 3+ __ __ __ 1+ 16:190     
__ +4  __ 4+  __ __ __ __ __ 4+  4+ __ 4+ 4+ 4+  __ __ 4+ __ __ 1+ 17:110     
+4 __ __ 3+ __ __ __ __ __ 3+ 4+ 2+ 4+ __ __ 4+ 4+ __ 4+ 4+ 4+ PTCC-1074
Table 1.  Antigenic schema with live organism antigens invitro by the slide agglutination test.
of P. aeruginosa were classified among the Iranian 
isolates. Each serotype was lyophilized, encoded and 
kept as stock culture in the Collection of Standard 
Bacteria of the Pasteur Institute of Iran (CSBPI) till 
use. Standard strain of P. aeruginosa PTCC-1074 was 
used as a positive control.
Antisera  preparation.  Each  P.  aeruginosa 
serotype was grown on Heart Infusion Agar (HIA) 
(MERK,  Darmstadt,  Germany)  for  18  hours  at 
37°C.  Cells  were  harvested  by  PBS  (Phosphate 
Buffer  Saline, pH = 7.2) containing 0.5% phenol 
and  2%  (V/V)  of  20%  glucose  solution.  Each 
suspension  was  heated  at  90°C for  one  hour  in 
shaking water bath and then washed three times with 
the same buffer. A portion of each cell suspension 
was  adjusted  to  9×108  cells/ml  in  sterile  PBS   
(pH  =  7.2)  and  then  used  as  immunizing  antigen.
A group of 2 white New Zealand rabbits, weighing 
1.5  to  2  Kg,  were  immunized  intravenously  with 
each serotype suspension in increasing doses of 0.25, 
0.5, 1, 1.5 and 2 ml at 4 day intervals 7 days after 
the last injection. The sera were collected from each 
group and pooled. After addition of 1:10000 (W/V) 
thiomersal, all sera were kept at 4°C till use. 
Rapid  slide  agglutination  test.  This  test  was 
applied for both the live and heat killed cells of all 16 87  SEROTyPINg OF Pseudomonas aeruginosa
isolates. PBS also used as negative control. Two drops 
of each antiserum was placed on a clean glass slide. A 
loop full of 18 hours growth from each live serotype 
was mixed evenly with the first drop and one drop of 
a thick suspension of each heat-killed cells was mixed 
second drop, slides were tilted by hand and the rate of 
agglutination  reaction was recorded from four positive 
(4+ means strong agglutination  appearing in a few 
seconds and one positive means a week agglutination 
reaction at the end of one minute) (19).
The  results  were  tabulated  so  that  the  rate  of 
agglutination of both live and killed bacteria from 
homologous  and  heterologous  strains  against  each 
serum was recorded.   
RESULTS
Comparison  of  the  results  observed  in  Tables 
1 & 2 show a minor antigenic difference between   
the  live  and  killed  antigens.  It  was  also  observed 
that  strains  10.55  and  15.14  had  the  highest                                                                             
agglutination  reaction  with  serum  of  all  the 
homologous  and  heterologous  serotypes  except 
serotype 8 and 9. Strain 1.101 had weak agglutination 
reaction. The sera against strains 6.95, 6.109, 7.107, 
17.110  had  maximum  agglutination  reaction  with 
homologous and heterologous strains. Strains 11.106 
and  15.14  showed  the  minimum  agglutination 
reaction.
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             Antiserum
          
         Antigen 
4+ 2+ __ __ __ __ __ __ 2+ __ __ 2+ __ __ 1+ __ 1+ __ 2+ 2+ 4+ 1:101       
__ __ 4+ __ 4+ __ __ __ 1+ __ __ 2+ __ __ 2+ __ 4+ __ 1+ 4+  __ 2:160       
__ 1+ __ __ __ __ __ __ 2+ __ __ 4+ __ __ 2+ 3+ 2+ __ 4+  __ 2+ 3:172
__ __ __ __ __ __ __ __ __ 2+ __ __ __ __ __ __ __ 4+  __ __ __ 4:89         
3+ 1+ __ 2+ 1+ __ __ 1+ 2+ 2+ 1+ __ 1+ 1+ 3+ 1+ 4+  1+ __ 3+ 4+ 5:60
__ __ 4+ __ 4+ __ __ __ __ __ __ __ __ __ __ 4+  4+  __ __ 4+ __ 5:111
__ 4+ __ __ __ __ __ __ __ 4+ 4+ __ 4+  4+  4+ __ __ __ __ __ __ 6:95
__ 4+ __ __ __ __ __ __ __ 4+ 4+  __ 4+  4+ 4+  __ __ __ __ __ __ 6:109
__ 4+ __ __ __ __ __ __ __ 4+ 4+ __ 4+  4+  4+ __ __ __ __ __ __ 7:107
__ __ __ __ __ __ __ __ __ __ __ 4+ __ __ __ __ __ __ 4+ __ __ 7:197
__ 4+ __ __ __ __ __ __ __ 4+ 4+  __ 4+ 4+  4+ __ __ __ __ __ __ 8:98         
__ 2+ __ __ __ __ __ __ 1+ 4+  __ __ 3+ __ 2+ 2+ __ __ 1+ __ __ 9:105
3+ 4+ __ 3+ 3+ __ __ 3+ 4+  3+ 3+ 4+ 4+ 4+ 4+ 4+ 3+ 4+ 4+ 4+ 4+ 10:55
__ __ __ __ __ __ __ 4+ 4+ __ __ __ __ __ __ __ __ __ __ __ __ 11:106
__ __ 1+ __ __ 4+ 4+ __ __ __ __ __ __ __ __ __ __ __ __ __ __ 12:80
__ __ 1+ __ __ 4+ 4+ __ __ __ __ __ __ __ __ __ __ __ __ __ __ 12:159
__ __ 4+ 1+ 4+  __ __ __ __ __ 4+ __ __ __ __ 4+ 4+ __ __ 4+ __ 13:108
3+ 4+ 4+ 4+  4+ 4+ 4+ 4+ 4+ 3+ 4+ 1+ 4+ 4+ 4+ 4+ 3+ 4+ 2+ 4+ 4+ 15:14
__ __ 4+ __ 4+ __ __ __ __ __ 4+ 1+ __ __ __ 1+ 4+ __ 1+ 4+ __ 16:190
___ 4+ __ __ __ __ __ __ __ 3+ 4+ __ 4+ 4+ 4+ __ __ __ __ __ __ 17:110
+4 __ __ __ __ __ __ __ __ __ 2+ 2+ __ __ __ __ __ __ __ __ 4+ PTCC-1074
Table 2. Antigenic schema with heat - stable somatic antigens invitro by the slide agglutination test.88 AHMADI    ET AL .                                                                                                                  IRAN. J. MICROBIOL. 2 (2) : 85-88 
DISCUSSION
Numerous epidemiological studies have revealed 
that more than 10% of all nosocomial infections and 
11%  of  all  organisms  isolated  from  blood  culture 
were P. aeruginosa. This rate increases to 30% in 
cancer  and  burn-wards  and  mortality  rate  among 
patients with septicemic infection rises to 80% (11). 
Resistance to different types of antibiotics and failure 
in response to drug treatment against P. aeruginosa 
infection has led to applying different ways of treating 
against this microorganism (17). Immunotherapy by 
vaccination or anti- P. aeruginosa hyperimmune sera 
can be a reliable method in controlling the infection 
(17, 18). 
Since the genetic structure of most P. aeruginosa 
serotypes  are  almost  similar,  determination  of  the 
extent of antigenic cross-reactivity between different 
serotypes leads us to design a reliable vaccine against 
the disease. Kusama et al (1978) in New York (1),   
Faure et al (2003) from California (5), Shigeta et al 
(1978) from Japan (7) and Liu (1987) from China (19) 
have reported classification and antigenic serotyping 
of P. aeruginosa. No vaccine production against P. 
aeruginosa has been reported so far in Iran and since 
the  common  strains  of  this  organism  are  different 
from each other in different geographical locations 
in terms of antigenicity, pathogenicity and medical 
resistance, producing a vaccine from common strains 
in Iran can be taken into consideration. As it can be 
observed  from  Table  1  and  2,  the  three  serotypes 
of 10.55, 15.14 and 8.98 or even just the first two 
serotypes of P. aeruginosa can be used in vaccine 
production. Due to the fact that these serotypes have 
shown the greatest antigenic similarities among the 
Iranian  isolates  of  P.  aeruginosa,  moreover,  they 
possibly can also be used in absorption of unwanted 
antibodies  from  hyper-immune  sera  against  each 
serotype to produce mono-specific antisera which are 
used in serotyping of P. aeruginosa isolates.  
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